Research in eye, gum, heart, kidney, reproductive and developmental biology, cancer, infections, high blood pressure, therapeutics development, microbiome, immunity, endometriosis, and osteoarthritis will advance with a combined $ 642,159 in support from Therapeutic Innovation Australia (TIA) and Phenomics Australia.
The Pipeline Accelerator scheme enables researchers to develop disease model systems to study, screen, optimise and validate drug candidates, test their efficacy and work towards industrial scale-up at advanced translational medical research facilities.
This round of the scheme is a partnership with Therapeutic Innovation Australia (TIA) to support a combined 19 research projects with access to 12 advanced facilities across Australia.
Recipients are academic researchers and small-to-medium enterprises (SMEs) working in translational medical research, from the molecular basis of health and disease through to clinical trials.
TIA CEO Dr Stuart Newman said the Pipeline Accelerator is a perfect vehicle for partnering, on the back of a successful scheme with the Australian Antimicrobial Resistance Network (AAMRNet) last year.
” Together, TIA and Phenomics Australia can seamlessly support national infrastructure to maintain research excellence, improve innovation and translation outcomes and address emerging challenges” he said.
” Partnering on the Pipeline Accelerator scheme is a tangible way we are driving a more integrated national research infrastructure ecosystem.”
” This, in turn, results in research outcomes that can deliver long term impacts to improve our standard of living, strengthen our economy and build sovereign capabilities to protect our nation from future medical threats.”
Phenomics Australia CEO Prof Michael Dobbie said:
” This scheme is intended to further reduce the cost of access to Phenomics Australia and TIA facilities and can be a great way to develop a track record in translational research for therapeutic discovery and development, particularly for early-career researchers (ECRs).”
” The general aims of the scheme are to provide a mechanism for financially supporting and enabling hard-to-fund therapeutic development projects, lowering barriers to entry and helping develop new research and industry user communities.”
” We collectively offer academic researchers and SMEs access to a broad range of Australian translational medical research advanced capabilities creating an ecosystem of seamless services leading to more effective use of national research infrastructure.”
Phenomics Australia’s Pipeline Accelerator awards:
Click here to see the TIA voucher recipients.
The new Phenomics Australia-supported Pipeline Accelerator scheme recipients include the following academic researchers and SMEs:
Click on the image to see the Phenomics Australia node involved
Prof James Hudson (QIMR Berghofer)
Phenomics Australia node: Induced Pluripotent Stem Cell Derivation & CRISPR Gene EditingFacility
Development of an epicardial lineage tracing human pluripotent stem cell line to identify new cardiac therapeutics
Dr Graham A. Mackay (The University of Melbourne)
Phenomics Australia node: Victorian Centre for Functional Genomics
MRGPRX2-dependent activation of mast cells: insight to novel therapeutic innovation
Dr Brett McKinnon (The University of Queensland)
Phenomics Australia node: Victorian Centre for Functional Genomics
High throughput screening of micro-organoids for assessing heterogeneity and precision medicine potential in endometriosis
Dr Zhian Chen (The University of Queensland)
Phenomics Australia node: Monash Genome Modification Platform
The role of ferroptosis and oxidative stress in regulating immunity
Dr Svenja Pachernegg (Murdoch Children's Research Institute)
Phenomics Australia node: Induced Pluripotent Stem Cell Derivation & CRISPR Gene EditingFacility
Using iPSCs to determine the role of NR2F2 in ovarian development and 46,XX sex reversal
Dr Ada Koo (The University of Melbourne)
Phenomics Australia node: Victorian Centre for Functional Genomics
Developing transcriptomic and morphological profiling of macrophages to mine the microbiome
Dr Alexander Nicholas Combes (Monash University)
Phenomics Australia nodes: Victorian Centre for Functional Genomics and Monash Functional Genomics Platform
New therapeutic strategies and targets to suppress acute kidney injury
Dr Simon Preston (Anaxis Pharma Pty Ltd)
Phenomics Australia node: Monash Organoid Program
Evaluating human organoids as model systems in drug development
A/Prof Edwina McGlinn (Monash University)
Phenomics Australia node: Monash Functional Genomics Platform
Tick tock, tick tock… Mechanisms pacing the Hox clock
About the Pipeline Accelerator:
TIA has developed the Pipeline Accelerator as a voucher-style researcher access scheme to facilitate and encourage access to our facilities. The scheme provides SMEs and researchers with access to one or more facilities associated with TIA to further reduce the cost of access to a specific capability. An external panel assesses projects for their scientific quality and potential for development of a therapeutic product.
About TIA:
TIA is a network of 25 national translational research infrastructure facilities in biologics and vaccines, cell and gene therapies, and small molecule pharmaceuticals. We aim to provide Australian researchers with access to the infrastructure to enable efficient translation of therapeutics to improve human health. Our investments ensure facilities are coordinated, comprehensive, accessible and responsive to the needs of the Australian translational research community. We financially support selected service providers to enable researcher access to subsidised, seamless, and value-adding expertise and support. Collectively, the TIA consortium enables translation of research findings into potential medical products, and towards readiness for Phase I trials and beyond.
About Phenomics Australia:
Phenomics Australia is a forward-thinking research infrastructure provider enabling research discovery and high-impact healthcare outcomes in precision medicine. Through 17 openly accessible service delivery centres across Australia, we offer specialised infrastructure, research services and technical expertise dedicated to advancing our fundamental understanding of health and disease, and enabling next-generation innovations in healthcare and therapeutic development to benefit all Australians. We will continue to develop our partnerships with prominent and emerging health initiatives and infrastructure providers, to establish integrated development pipelines for research discovery and translation.
